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ABSTRACT
Introductions: The termination of second trimester pregnancy is challenging 
due unfavorable cervix. This study evaluate the efficacy and maternal side 
effects of intravaginal misoprostol for termination of second trimester 
pregnancy.
Methods: During one year period from 15th June 2011 to 14th June 2012, 
Department of Obstetrics and Gynaecology of Patan Hospital, women admitted 
for second trimester termination of pregnancy for fetal congenital anomalies 
and intrauterine fetal demise were studied using the International Federation 
of Gynaecology and Obstetrics recommended doses of vaginal misoprostol. 
For congenital anomalies, 400 mcg  3 hourly to a maximum of 5 doses were 
used. For fetal demise, gestational age of 13-17 weeks received 200 mcg every 
6 hourly to a maximum of 4 doses, and 18-26 weeks dose was adjusted to 
100 mcg. Main outcome measures included success rate of abortion within 48 
hours, induction to delivery interval and maternal side effects.
Results: There were 40 patients during study period. Success rate for termination 
of 2nd trimester pregnancy within 48 hours was 88.8% for congenital anomalies. 
For fetal demise, success of termination was 90.9% at 13-17 weeks and 100% 
at 18-26 weeks. Median time from induction to delivery was 26.8 hours  for 
congenital anomalies. For fetal demise, it was 18 hours for 13-17 weeks was 
and 24 hours at 18 to 26 weeks respectively. Abdominal pain was seen in all 
doses of misoprostol. 
Conclusions: Vaginal misoprostol is an effective method for termination of 
second trimester pregnancy.
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Plain Language Summary 
The study was conducted to see the effectiveness of vaginal misoprostol for 
termination of second trimester pregnancy. The success rate of termination for 
congenital abnormality and fetal demise was high. Vaginal misoprostol was an 
effective method for termination of second trimester pregnancy.
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INTRODUCTIONS
The termination of second trimester pregnancy is risky 
because of its complications and psychological trauma to 
patients. It constitutes 10-15% of all induced abortions 
usually done for intrauterine fetal demise (IUFD), fetal 
congenital anomalies and medical disorders associated 
with pregnancy.1 Early detection of lethal structural and 
chromosomal abnormalities, and IUFD has increased 
the demand of rapid second trimester termination.2 The 
termination of second trimester pregnancy is a significant 
problem in the presence of unfavorable cervix and is 
often prolonged and tedious.3
Among various methods of second trimester termination, 
evacuation and curettage induces risk of bleeding, 
infection, uterine perforation and cervical trauma.4 The 
introduction of misoprostol, a synthetic prostaglandin 
E1 analog (PGE1) has become an important for cervical 
ripening and uterotonic action.5 It is economic, stable 
at room temperature and is associated with few side 
effects such as fever, vomiting and diarrhea.6-12 There 
is still debate about doses, routes and regimes of PGE1 
for termination of pregnancy during second.7 Studies 
have demonstrated greater efficacy with vaginal 
misoprostol than oral misoprostol.8-10 The Federation of 
International of Gynecologists and Obstetricians (FIGO) 
recommendation for second trimester termination with 
vaginal misoprostol states “400 mcg at 3 hours interval 
to a maximum of 5 doses for induction of congenital 
anomalies and for IUFD, the doses are adjusted to 
gestational age: 13-17 weeks 200 mcg every 6 hours to 
a maximum of 4 doses, and for 18-26 weeks 100 mcg 
every 6 hours to a maximum of 4 doses”.11 The aim of this 
study was to assess the efficacy and maternal side effects 
of misoprostol as per FIGO guidelines for termination of 
second trimester pregnancy.
METHODS
This was a cross sectional study of one year period from 
15th June, 2011 to 14th June 2012 in the Department 
of Obstetrics and Gynecology, Patan Hospital. Forty 
pregnant women with fetal congenital anomalies and 
intrauterine fetal demise (IUFD) admitted for second 
trimester (13-26 weeks) termination were included. 
Counseling was done regarding the procedure, 
advantages and disadvantages and possible side effects. 
Informed consent were obtained. The gestational age 
was determined by menstrual history, pelvic examination 
and confirmed by ultrasound when last menstrual period 
(LMP) was not confirmed. Routine investigations were 
done including blood grouping, hematocrit, platelets 
and random blood sugar. Exclusion criteria were known 
hypersensitivity to prostaglandins, previous caesarean 
section or any surgical intervention in uterus, gravidity 
more than five, intrauterine contraceptive device in situ, 
low lying placenta, hydatidiform mole, ectopic pregnancy, 
adnexal mass, cardiac disease and coagulopathy.
We followed vaginal misoprostol as per FIGO protocol.11 
The misoprostol tablets were placed in the posterior 
vaginal fornix. Cervical status was assessed by vaginal 
examination before insertion of next dose or at the 
onset of uterine contraction. Pethidine hydrochloride 
50 mg intramuscularly was given for abdominal pain. 
acetaminophen 500mg oral for fever (temperature ≥ 
100.4o F), and metoclopramide (10 mg) intravenous for 
vomiting.
Treatment success was defined as expulsion of the 
fetus within 48 hours after the insertion of initial dose 
of misoprostol. Induction to delivery interval was 
defined as the time from the initial dose of misoprostol 
to the expulsion of fetus. Maternal side effects such as 
abdominal pain, fever (temperature ≥ 100.4o F), nausea, 
vomiting, diarrhea and excessive bleeding requiring blood 
transfusion based on clinical examination and hematocrit 
less than 23% were recorded. Completion of termination 
was assessed by visual examination of abortus, bleeding, 
pain, and vaginal examination to see the status of cervical 
os. Uterine curettage was performed if retained product 
of conception was detected on vaginal examination after 
expulsion of fetus and placenta. All women who did not 
abort within 48 hours of misoprostol induction, depending 
on their cervical status and amniotic membrane integrity 
received a transcervical Foley catheter 18 Fr, balloon 
inflated with 50 ml of distilled water and kept in situ for 
24 hours or intravenous oxytocin infusion.
Statistical Package for Social Sciences (SPSS) version 13 
was used for descriptive analysis.
The study was approved by the institutional review 
committee of PAHS. 
RESULTS
There were forty women, 31 with IUFD and nine 
congenital anomalies for termination of pregnancy 
during the second trimester of 13-26 weeks. 
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Table 1. Characteristics of patient undergoing second trimester 
abortion (n= 40)
Characteristics
Mean Age ± SD (years) 26.30 ± 5.04
Mean GA ± SD (weeks) 20.32 ± 4.05
Mean Gravidity ± SD 1.88 ± 1.04
Primigravida 19 (47.50%)
Multigravida 21 (52.50%)
Congenital Anomalies 9 (22.50%)
IUFD 31 (77.50%)
Note: n = Total number of patients, SD = Standard Deviation, GA = Gestational Age, 
IUFD= intrauterine fetal demise
Of 31 fetal IUFD, 11 (35.49%) were of gestational age 13-
17 weeks and 20 (64.51%) of 18-26 weeks.
At 48 hours, the successful termination in 31 IUFD was 
90.9% (10 of 11) at 13 to 17 weeks and 100% (20 0f 20) 
at 18-26 weeks. The success rate was 88.8% (8 of 9) for 
congenital anomalies. Median induction to delivery time 
was 26.8 hours with 400 mcg Misoprostol for congenital 
anomalies. For IUFD, it was 18 hours with 200 mcg at 13 
to 17 weeks and 24 hours  with 100 mcg at 18 to 26 weeks 
Table 2. Vaginal Misoprostol induction to delivery time in patient 


















 Number of 
patients with






(q1*,q3*) <48 hrs >48 hrs
400 9 20.36 ± 3.44
5 (8; 88.9) 7 1 26.8
(20, 41.5)4 (1; 11.1) 1 0
200 11 15.90 ± 1.81
2 (3; 27.3) 3 0 18
(12, 26)4 (8; 72.7) 7 1
100 20 22.73 ± 3.09
1 (2; 10) 2 0
24
(14, 26)
2 (3; 15) 3 0
3 (1; 5) 1 0
4 (14; 70) 14 0
Q= quartile
For women who did not abort within 48 hours of 
misoprostol induction, 11.2% (1 of 9) for congenital 
anomalies received trans-cervical Foley catheter whereas 
9.1% (1 of 11) for IUFD at 13 to 17 weeks received 
intravenous oxytocin infusion. All of them expelled the 
fetus successfully. 
Abdomen pain was seen at all doses and nausea vomiting 
at high dose of misoprostol 
Table 3. Maternal complications of vaginal Misoprostol induction in 
patient undergoing second trimester abortion (n=40)
Side Effects
400 mcg (N=9) 200 mcg (N=11) 100 mcg (N = 20)
N % N % N %
Abdominal pain 4 44.44 6 54.54 5 25
Pyrexia (>100.40F) 1 11.11 0 0 0 0
Nausea vomiting 2 22.22 0 0 0 0
None of our patient required transfusion for excessive 
bleeding. There was no mortality in this series.
DISCUSSIONS
In this study the success rate within 48 hours of 
misoprostol induction was 88.8% (8 of 9) for congenital 
anomalies which is comparable to 90.5%.12 For IUFD, the 
success rate was 90.9% (10 of 11 cases of 13 to 17 weeks) 
and 100% (20 0f 20 cases of 18-26 weeks), higher than 
87.2% reported by Jain et al.5
The required amount of misoprostol not only decreases 
with increasing gestational age, but has also been found 
to be lower in women with a dead fetus. This may be due 
to intrinsic changes in the uterus and cervix that make 
the myometrial cells sensitive to stimulant and cervical 
tissues favorable to ripening agent after fetal death.12 
The cervix of pregnant women with dead fetus tends to 
efface more readily and dilate when compared with that 
of the live fetus.12 J. Srisomboon and S. Pongpisuttinun 
have also concluded that intrauterine fetal death had 
higher success rate and aborted earlier than those with a 
live fetus by comparing the efficacy and safety of 200 mcg 
of intravaginal misoprostol administered every 12 hours 
between live and dead fetuses in second trimester.17
In this study, the median induction to delivery interval 
was 26.8 hours (Q1, Q3: 20, 41.5 hours) in 400 mcg for 
congenital anomalies whereas 18 hours (Q1, Q3: 12, 26 
hours) in 200 mcg for IUFD at 13 to 17 weeks and 24 
hours (Q1, Q3: 14, 26 hours) in 100 mcg for IUFD at 18 to 
26 weeks respectively. 
Several studies have evaluated the use of misoprostol for 
induction of labour in the second trimester.1-3 There are 
different regimes for the use of misoprostol in termination 
of second trimester pregnancy.13 In this study, we used 
the protocol recommended by the FIGO for second 
trimester termination with vaginal misoprostol: 400 mcg 
at every 3 hours interval to a maximum of 5 doses for 
induction of congenital anomalies. For IUFD, doses were 
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adjusted to gestational age: between 13-17 weeks 200 
mcg every 6 hours interval to a maximum of 4 doses, and 
between 18-26 weeks 100 mcg every 6 hours interval to 
a maximum of 4 doses.11
The most common maternal side effects observed in this 
study were abdominal pain followed by nausea, vomiting 
and pyrexia.  Symptomatic management was successful. 
Other authors have observed fever as the most frequent 
side effects.13-17
CONCLUSIONS
Vaginal misoprostol was effective with minimal side 
effects for termination of second trimester pregnancy for 
fetal congenital anomalies and intrauterine fetal demise.
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